Solid Tumors
CASE 2Y15
Identifying and overcoming barriers to precision oncology among racial and ethnic minorities.
View full trial information.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Prostate Cancer
CASE 3815
The effectiveness of a proposed Prostate Cancer outreach program in a predominantly African American community that promotes informed decision-making for prostate cancer screening and utilizes community navigation.
View full trial information.
Head and Neck Cancer
CASE 6316
A Phase II Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck.
View full trial information.
CAR T-cell Therapy
CASE 11Z18
This study aims to develop a repository of blood samples from patients receiving CAR T-cell therapy at the Cleveland Clinic.
View full trial information.
Leukemia, Acute Myeloid (AML)
MNGP 1917
A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia; CLI24-001.
View full trial information.
Multiple Myeloma
JAN 2A17
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma
View full trial information.
Leukemia, Acute Myeloid (AML), Leukemia, Chronic Myeloid (CML), Myelofibrosis, Myeloproliferative Neoplasms
MCC 1917
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination with Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms.
View full trial information.
Search our Cancer Clinical Trials Database for a full listing of all open and accruing studies.
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy